Progressive degeneration of human neural stem cells caused by pathogenic LRRK2

Nature

Volumn 491, Issue 7425, 2012, Pages 603-607

  Liu, Guang Hui ^a,b   Qu, Jing ^a,b   Suzuki, Keiichiro ^b   Nivet, Emmanuel ^b   Li, Mo ^b   Montserrat, Nuria ^c   Yi, Fei ^b   Xu, Xiuling ^a   Ruiz, Sergio ^b   Zhang, Weiqi ^a   Wagner, Ulrich ^d   Kim, Audrey ^d   Ren, Bing ^d   Li, Ying ^a   Goebl, April ^b   Kim, Jessica ^b   Soligalla, Rupa Devi ^b   Dubova, Ilir ^b   Thompson, James ^e   Iii, John Yates ^e   Esteban, Concepcion Rodriguez ^b   Sancho Martinez, Ignacio ^b   Belmonte, Juan Carlos Izpisua ^b,c   more..

^a INSTITUTE OF BIOPHYSICS   (China)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; LAMIN B; LEUCINE RICH REPEAT KINASE 2; SERINE;

ADULT; AGING POPULATION; AMINO ACID; CELL ORGANELLE; DISEASE PREVALENCE; EMBRYONIC DEVELOPMENT; NEUROLOGY; PATHOGENICITY; PATHOLOGY; PHENOTYPE; RODENT;

AGING; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CELL NUCLEUS MEMBRANE; CELL POPULATION; CELL STRUCTURE; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PARKINSON DISEASE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL EXPANSION;

APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CLONE CELLS; EMBRYONIC STEM CELLS; GENE KNOCK-IN TECHNIQUES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MUTANT PROTEINS; MUTATION; NEURAL STEM CELLS; NUCLEAR ENVELOPE; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; STRESS, PHYSIOLOGICAL;

MUS;

EID: 84869877601     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11557     Document Type: Article

References (30)

1. Liu, G. H. et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221-225 (2011).
2. Dechat, T. et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 22, 832-853 (2008).
3. Kudlow, B. A., Kennedy, B. K. & Monnat, R. J., Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basisofhuman progeroid diseases. Nature Rev. Mol. Cell Biol. 8, 394-404 (2007).
4. Worman, H. J., Ostlund, C. & Wang, Y. Diseasesofthe nuclear envelope. Cold Spring Harb. Perspect. Biol. 2, a000760 (2010).
5. Winner, B. et al. Adult neurogenesis and neurite outgrowth are impairedinLRRK2 G2019S mice. Neurobiol. Dis. 41, 706-716 (2011).
6. Chang, K. H. et al. Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death. Mol. Biol. Cell 22, 1452-1462 (2011).
7. Tran, D., Chalhoub, A., Schooley, A., Zhang, W. & Ngsee, J. K. A mutation in VAPB that causes amyotrophic lateral sclerosis also causes a nuclear envelope defect. J. Cell Sci. 125, 2831-2836 (2012).
8. Padiath, Q. S. et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nature Genet. 38, 1114-1123 (2006).
9. Woulfe, J. M. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol. Appl. Neurobiol. 33, 2-42 (2007).
10. Cookson, M. R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Rev. Neurosci. 11, 791-797 (2010).
11. Cookson, M. R. & Bandmann, O. Parkinson's disease: insights from pathways. Hum. Mol. Genet. 19, R21-R27 (2010).
12. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chem. Biol. 7, 203-205 (2011).
13. Lee, B. D. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Med. 16, 998-1000 (2010).
14. Li, W. et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc. Natl Acad. Sci. USA 108, 8299-8304 (2011).
15. Krishnan, V. et al. HistoneH4lysine16 hypoacetylationisassociated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc. Natl Acad. Sci. USA 108, 12325-12330 (2011).
16. Cheung, I. et al. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc. Natl Acad. Sci. USA 107, 8824-8829 (2010).
17. Xie, W. et al. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J. Neurochem. 115, 188-199 (2010).
18. Liu, G. H. et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8, 688-694 (2011).
19. Suzuki, K. et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc. Natl Acad. Sci. USA 105, 13781-13786 (2008).
20. Li, M. et al. Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res. 21, 1740-1744 (2011).
21. Aizawa, E. et al. Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors. Mol. Ther. 20, 424-431 (2012).
22. Rudenko, I. N., Chia, R. & Cookson, M. R. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med. 10, 20 (2012).
23. Kanao, T. et al. Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum. Mol. Genet. 19, 3747-3758 (2010).
24. Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637-641 (2010).
25. Nichols, R. J. et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393-404 (2010).
26. Dzamko, N. et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 430, 405-413 (2010).
27. Scaffidi, P. & Misteli, T. Lamin A-dependent nuclear defects in human aging. Science 312, 1059-1063 (2006).
28. Poulopoulos, M. et al. Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD. J. Mol. Neurosci. 47, 139-143 (2012).
29. Thaler, A., Mirelman, A., Gurevich, T., Simon, E., Orr-Urtreger, A., Marder, K., Bressman, S. & Giladi, N. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 79, 1027-1032 (2012).
30. Tiscornia, G., Vivas, E. L. & Belmonte, J. C. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nature Med. 17, 1570-1576 (2011).